triple glp-1/gip/glucagon receptor agonist New strategies for the treatment of obesity and metabolic dysfunctions Science Behind GLP 1 GIP
Description
Latin America is expected to grow at a significant CAGR during the forecast period
Paracardiac adipose tissue (EAT and pericardial fat) decreased by 45 mL in the tirzepatide group ( p 30, is a significant contributor, with up to 80% of obese individuals developing MAFLD [37]
RosenstockJPerkovicVJohansenOECooperMEKahnSEMarxNet al
Furthermore, some DPP-4 inhibitors have specific features that make them safe to use in patients with CKD without the need for dose adjustment and are therefore necessary in this subset [34]
Centers for Disease Control and Prevention
